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  Abstract 
    Background aims.   Mesenchymal stromal cells (MSC) are the focus of research in regenerative medicine aiming at the 
regulatory approval of these cells for speciﬁ  c indications. To cope with the regulatory requirements for somatic cell therapy, 
novel approaches that do not interfere with the natural behavior of the cells are necessary. In this context   in vivo   magnetic 
resonance imaging (MRI) of labeled MSC could be an appropriate tool. Cell labeling for MRI with a variety of different 
iron oxide preparations is frequently published. However, most publications lack a comprehensive assessment of the non-
interference of the contrast agent with the functionality of the labeled MSC, which is a prerequisite for the validity of 
cell-tracking via MRI.   Methods  . We studied the effects of iron oxide  –  poly(  L  -lactide) nanoparticles in MSC with ﬂ  ow cytom-
etry, transmission electron microscopy (TEM), confocal laser scanning microscopy (CLSM), Prussian blue staining, 
CyQuant  ®   proliferation testing, colony-forming unit  –  ﬁ  broblast (CFU-F) assays, ﬂ  ow chamber adhesion testing, immuno-
logic tests and differentiation tests. Furthermore iron-labeled MSC were studied by MRI in agarose phantoms and Wistar 
rats.   Results  . It could be demonstrated that MSC show rapid uptake of nanoparticles and long-lasting intracellular persist-
ence in the endosomal compartment. Labeling of the MSC with these particles has no inﬂ  uence on viability, differentiation, 
clonogenicity, proliferation, adhesion, phenotype and immunosuppressive properties. They show excellent MRI properties 
in agarose phantoms and after subcutaneous implantation in rats over several weeks.   Conclusions  . These particles qualify 
for studying MSC homing and trafﬁ  cking via MRI.     
    Introduction 
  Mesenchymal stromal/stem cells (MSC) are the 
focus of interest in regenerative medicine, nurtured 
by their proven ability to differentiate into differ-
ent cell types deriving from the mesoderm and 
their abundant availability because they are easy to 
culture and expand   in vitro   (1,2). Potential clinical 
applications are mainly in the ﬁ  eld of bone, carti-
lage, skin, kidney and myocardial repair and immu-
nomodulation (2  –  8). MSC can inhibit proliferation 
of T, B and   natural killer (NK) cells and may inter-
fere with function of dendritic cells (2). Because of 
their strong immunosuppressive potential, MSC also 
show promise for treatment of immunologic disor-
ders (2). MSC are derived from different origins 
(bone marrow, adipose tissue, cord blood and oth-
ers). They lack characterization by a unique, quali-
fying marker. The International Society of Cellular 
Therapy (ISCT) published a minimum set of crite-
ria to deﬁ  ne MSC (9); however, differences in MSC 
from different origins and in different culture condi-
tions have been observed (10  –  13). Currently it is not 
known whether MSC act by differentiating into new 
tissue or by paracrine action, or a combination. Also, 
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the optimal application mode and dose in different 
pathologies is under investigation (11  –  15). Studies 
on dose and biodistribution are important aspects of 
the assessment of the safety of MSC. They are con-
sidered to be an advanced therapy medicinal product 
(ATMP). The new European Union (EU) Directive 
2009/120/EC amending Directive 2001/83/EC stip-
ulates requirements for marketing and authorization 
of ATMP (16,17). This Directive requests data on 
  ‘  biodistribution, persistence and long-term engraft-
ment of the somatic cell therapy medicinal product 
components  ’   (17). In this context   in vivo   tracking 
of MSC offers interesting opportunities, adding a 
new, non-invasive tool. Magnetic resonance imaging 
(MRI) is technically suitable to serve this need, but 
requires contrast labeling of the MSC administered. 
As the impact of changes in culture conditions and 
other manipulations on MSC is not fully elucidated 
yet, a contrast agent qualifying for MSC labeling   
in vivo   must fulﬁ   ll at least the following criteria 
  in vitro  : proven intracellular uptake and intracellular 
retention over time in quantities that change the MRI 
signal; no change of viability of the cells; no change 
in the set of MSC criteria as deﬁ  ned by ISCT; no 
alteration of MSC functionality; and a robust label-
ing procedure with only minimal interference with 
the   ex vivo   MSC expansion process. 
  The incorporation of different iron oxide-loaded 
particles in MSC and their MRI properties   in vitro   
and   in vivo   has been shown by several groups (18  –
  30). However, effects of iron-labeling on the biologic 
function, phenotype, differentiation potential and 
clonogenicity of MSC are controversially reported. 
Some groups report changes, whereas others do not 
see any differences underlining the importance of a 
comprehensive assessment for each labeling approach 
(31  –  34). Up to now, a systematic and comprehen-
sive evaluation of the suitability of a speciﬁ  c MRI 
contrast agent/labeling technique for MSC labeling 
with regard to its lack of inﬂ  uence on MSC function 
is missing. Also, in most published studies data on 
kinetics, if provided at all, focus on uptake and do 
not provide detail on retention of the contrast agent. 
This information is essential for the interpretation 
of MRI data in long-term MRI observation studies, 
and important for deﬁ  ning the optimal labeling and 
labeled cell administration regimen. In the study pre-
sented here, we investigated MSC labeling with iron 
oxide  –  poly(  L  -lactide) (PLLA) nanoparticles synthe-
sized via the mini-emulsion process (35,36). These 
nanoparticles have distinct advantages: PLLA is a 
polymer with a long history of safe use in medical 
applications and is fully biodegradable (37,38). The 
mini-emulsion process allows further introduction 
of different concentrations and types of iron oxide 
into the nanoparticles for optimization of the MRI 
properties, and also a ﬂ  uorescent dye embedded in 
the polymer. The nanoparticles investigated have a 
negative zeta potential (between   –  29 and   –  44 mV) 
and a diameter of 110  –  135 nm. 
  Intracellular uptake and retention was evaluated 
quantitatively by flow cytometry and qualitatively 
by transmission electron microscopy, confocal laser 
scanning microscopy and Prussian blue staining. 
Expression of surface markers was determined by ﬂ  ow 
cytometry, and MSC differentiation into the osteo-
blastic, adipogenic and chondrogenic lineages was 
induced and observed by standard methods. MSC 
functionality was tested by colony-forming unit  –
  fibroblast assay (CFU-F), proliferation and MSC 
adhesion on human umbilical vein endothelial cells 
(HUVEC) cells under shear stress. MRI properties   
in vitro   (agarose phantoms) and   in vivo   (white Wistar 
rats) were evaluated using a 3-Tesla clinical scanner.     
  Methods 
  The nanoparticles were prepared with a mini-
emulsion  process (35). The nanoparticles tested 
were composed of poly(  L  -lactide) as a polymer 
and wuestite or magnetite as iron oxide (36). The 
particles were labeled with the ﬂ   uorescent dye   N  -
(2,6-diisopropylphenyl)-perylene-3,4-dicarbonacid-
imide (PMI) (36).   
  Materials 
  Ferric chloride hexahydrate (FeCl  3    ·  6 H  2  O; 99%; Merck, 
Darmstadt, Germany), oleic acid (58%; Riedel-de 
Haen, Seelze, Germany), methanol (98.5%; Merck), 
sodium hydroxide (99%; Merck),   L  -octadecene (92%; 
Merck), acetone (99%; Merck),   n  -octane (95%; Fluka, 
Buchs, Switzerland), Biomer    ®   L9000 (number average 
molecular weight (  M    n  ))   c.   66 500 g/mol,   weight aver-
age molecular weight (M    w  )   c.   145 000 g/mol, deter-
mined by gel permeation chromatography (GPC) in 
chloroform; Biomer, Krailing, Germany), chloroform 
(99.99%; Fisher Scientiﬁ   c, Schwerte, Germany), 
sodium   n  -dodecyl sulfate (SDS; 99%; Alfa Aesar), PMI 
(BASF, Ludwigshafen, Germany) and hydrochloric 
acid (37%; AnalaR NORMAPUR; Prolabo, Leuven, 
Belgium). All chemicals were used as received. Demin-
eralized (demin) water was used throughout the work.     
  Synthesis of hydrophobized iron oxide nanoparticles 
  The synthesis was performed as described else-
where (39). Brieﬂ   y, NaOH (2.4 g) was dissolved 
in methanol (200 mL) and dropped into a solu-
tion consisting of FeCl  3    ·  6 H  2  O (5.4 g), oleic acid 
(17 mL) and methanol (100 mL). The brown precip-
itate obtained was washed ﬁ  ve times with methanol 
and dried under reduced pressure. Afterwards, the 
brown solid was dissolved in   L  -octadecene (100 mL) 964  G. Schmidtke-Schrezenmeier et al. 
at 70  °  C and 3 equivalent excess of oleic acid (for 
25 nm wuestite particles) or 1 equivalent of oleic acid 
(for 10 –  25 nm magnetite particles) was added and the 
mixture heated to 300  °  C for 30 min under stirring in 
an argon atmosphere. By adding acetone:methanol 
at a 1:1 ratio, the iron oxide nanoparticles were pre-
cipitated and separated from the solution. The iron 
oxide nanoparticles were redispersed in   n  -octane and 
precipitated again by adding acetone:methanol and 
centrifuged again. The black residue obtained was 
dried at 40  °  C under reduced pressure.     
  Preparation of poly(  L  -lactide) particles with 
encapsulated iron oxide 
  PLLA (300 mg), PMI (0.23 mg) and 150 mg of 
hydrophobized iron oxide nanoparticles were dis-
persed in chloroform (10 g) at 40  °  C and mixed after-
wards with a solution consisting of water (24 g) and 
SDS (72 mg). After mechanical stirring for 1 h at 
500 r.p.m., the mini-emulsion was prepared by ultra-
sonication for 180 s (30-s pulse, 10-s pause) at 70% 
amplitude using a Branson soniﬁ  er W450 digital with 
a   ½  " tip under ice cooling, in order to prevent the 
evaporation of chloroform. The mini-emulsion was 
transferred into a round-bottomed ﬂ  ask with a wide 
neck and heated at 40  °  C under mechanical stirring 
(400 r.p.m.) overnight to evaporate the chloroform. 
The particles were puriﬁ  ed to reduce the amount 
of surfactant and remove the non-encapsulated iron 
oxide and PMI. Therefore the sample was ﬁ  rst cen-
trifuged for 20 min at 420   g   and then the upper phase 
was transferred into another tube. The sample was 
dialyzed (MWCO 100 000 membrane) by centrifu-
gation for 30 min each at 690   g   until the conductivity 
reached values below 9   μ  S/cm.     
  Characterization of the particles 
  The particle size and zeta potential were measured 
using a Malvern Instruments Zeta Nanosizer with 
a detection angle at 173  °  , or a PSS NICOMP 380 
Submicron Particle Sizer. The zeta potential was 
measured in a 10    –  3     M   KCl solution. For transmis-
sion electron microscopy, a Philips EM 400 or Zeiss 
EM 902 transmission electron microscope, both 
working at 80 kV, was used. Polymer particles were 
diluted with water, dropped on a carbon-coated 300-
mesh copper grid, dried at ambient temperature and 
coated with carbon afterwards. 
  The amount of entrapped ﬂ  uorescent marker was 
determined from the ultraviolet (UV)  –  visible absorp-
tion spectra of the particles. The measurements 
were carried out on an UV  –  visible spectrometer 
Lambda 16 from Perkin Elmer, Rodgau, Gemany; 
5.6 mg of the freeze-dried sample was dissolved in 
1 g chloroform. The iron oxide was decomposed 
using concentrated hydrochloric acid (37%) and the 
organic phase was washed afterwards three times 
with demin water. The chloroform phase was dried 
overnight under reduced pressure at 40  °  C and the 
solid was dissolved in the initial amount of chloro-
form afterwards. The absorbance of the solution was 
measured at 479 nm, which corresponded to a peak 
maximum for PMI. The amount of iron was deter-
mined by inductively coupled plasma-optical emis-
sion spectrometry (ICP-OES) with a Horiba Jobin 
Yvon Activa M. The sample was diluted (1:100) with 
a 0.75wt% SDS solution.     
  Cultivation of human MSC 
  Cryopreserved   in vitro  -expanded human bone marrow-
derived MSC of different passages were provided by 
the Institute of Transfusion Medicine of the Uni-
versity of Ulm (Ulm, Germany). Informed consent 
was obtained for collection of the original probe and 
covered by institutional review board (IRB) approval. 
Heparinized, unmanipulated bone marrow was seeded 
in cell culture ﬂ  asks (Nunc, Roskilde, Denmark) in 
alpha-Minimum essential medium (MEM) (Lonza, 
Verviers, Belgium) and supplemented either by 20% 
fetal calf serum (FCS; Gibco fetal bovine serum; 
Invitrogen, Grand Island, NY, USA) or 10% human 
platelet lysate (PL; Institute for Clinical Transfusion 
Medicine and Immunogenetics, Ulm, Germany) (40). 
After 72  –  96 h, non-adherent cells were washed off and 
new medium was added. A medium exchange was 
performed weekly until cultures were almost con-
ﬂ  uent. Alpha-MEM with 10% PL (supernatant after 
cen  trifugation at 5000 r.p.m.) was supplemented with 
12   μ  g/mL ciproﬂ  oxacin (Fresenius Kabi, Bad Hom-
burg, Germany) and 2 IU/mL heparin (Ratiopharm, 
Ulm, Germany), in order to avoid clot formation 
and clumping of MSC. Alpha-MEM with 20% FCS 
was supplemented with 100 IU penicillin, 100   μ  g 
streptomycin (PenStrep Gibco; Invitrogen), 12   μ  g 
ciproﬂ  oxacin and 0.1 mg sodium pyruvate (Sigma, 
Munich, Germany) per mL medium. Cells were 
grown in a humidiﬁ   ed incubator at 37  °  C and 5% 
CO  2  . MSC used in this study had shown osteogenic, 
chondrogenic and adipogenic differentiation. 
  For passaging/harvesting of the cells, medium 
was removed and cells were washed once with phos-
phate-buffered saline (PBS) and incubated with 
0.5% trypsin (Invitrogen, Burlington,  Canada) for 
4  –  8 min at 37  °  C; detachment was checked visually 
before trypsin activity was neutralized with the addi-
tion of equal volumes of supplemented medium. 
For the experiments MSC were used between pas-
sages 1 and 10 (detailed information in the ﬁ  gure 
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USA) was added, which was excited by 543 nm laser 
light. Images were taken in the Kalman ﬁ  lter mode.     
  Transmission electron microscopy 
  Cells were ﬁ  xed with 2.5% glutaraldehyde contain-
ing 1.5% saccharose and 0.1   M   phosphate buffer 
in PBS (pH      7.3) and post-ﬁ  xed in 2% aqueous 
osmium tetroxide. The samples were dehydrated 
in a 1-propanol series, block stained in 1% uranyl 
acetate and embedded in Epon. Ultra-thin sections 
were imaged in a Philips EM400 TEM, which was 
operated at a voltage of 80 kV.     
  Flow cytometric analysis 
  For quantiﬁ   cation of cellular particle uptake and 
determination of cell viability via 7-aminoactinomy-
cin (7-AAD; Sigma Aldrich, St.Louis, MO, USA) 
staining, a FACSscan (Becton Dickinson) was 
used. Data were acquired and analyzed with Cell-
quest 3.3 software (Becton Dickinson). Cells were 
washed, trypsinized and incubated for 15 min with 
20 mg/mL 7-AAD and washed. FL1 was analyzed 
for nanoparticle uptake and FL3 for 7-AAD assess-
ment. To allow comparison of uptake of different 
nanoparticles, FL1 values were normalized (nFL1). 
For this, the ﬂ  uorescence signal was divided by the 
concentration of incorporated PMI in the particle. 
Surface antigens were analyzed with FACS-Aria  ®   
(Becton Dickinson). Commercial antibodies were 
used according to the recommendations of the 
manufacturers: CD3  –  Allophycocyanin (APC)  –  Cy7, 
CD9  –  APC, CD11b  –  phycoerythrin (PE), CD14  –
  PE, CD16  –  PE, CD19  –  PE  –  Cy7, CD29  –  PE, CD45  –
  Peridinin Chlorophyll Protein Complex (PerCP), 
CD61  –  PerCP, CD71  –  APC, CD73  –  PE, CD90  –  PE, 
CD105  –  ﬂ  uorescein isothiocyanate (FITC), CD166  –
  PE, HLA-A, -B, -C  –  APC, anti-mouse IgG1  –  APC, 
anti-mouse IgG1  –  PE, anti-mouse IgG1  –  PE  –  Cy7, 
anti-mouse IgG1  –  PerCP, anti-mouse IgG1  –  APC  –
  Cy7 (BD Biosciences, San Jose, CA, USA), CD13  –
  APC, CD105  –  APC (Caltag Labs, Burlingame, 
CA, USA), CD133  –  APC, CD271  –  APC (Miltenyi 
Biotec); HLA-DR  –  APC (R&D Systems, Minneapo-
lis, MN, USA) and SSEA  –  4   –  APC (eBioscience, 
San Diego, CA, USA).     
  Adhesion under ﬂ  ow 
  The scope of this test was the analysis of MSC 
adhesion behavior under shear stress. HUVEC were 
seeded into   μ   slides (Ibidi Systems, Munich, Ger-
many) in endothelial cell growth medium, as described 
previously (41). After reaching conﬂ  uency, HUVEC 
were treated overnight with 100 ng/mL recombinant 
from different passages did not show signiﬁ  cant dif-
ferences of results. The number of population dou-
blings of MSC that were used in the experiments 
ranged from 12.5 to 41.     
  Prussian blue staining 
  Cytospins of MSC were prepared on glass slides. The 
slides were air dried for at least 30 min. Slides were 
ﬁ  xed in methanol for 10 min and then incubated for 
17 min in freshly prepared potassium hexacyanofer-
rate (II) solution 2% w/w, with 0.1 N Hydrochloric 
acid (HCL), and washed in distilled water, counter-
stained with hematoxylin-eosin for 5 min, washed 
three times in distilled water and air dried.     
  Differentiation of human MSC 
  For the adiopogenic differentiation assay, adipogenic 
induction medium (PT-3102B; Lonza) was used. 
After 3  –  4 days, induction medium was removed and 
substituted by adipogenic maintenance medium for 
3  –  4 days (PT3102A; Lonza). This cycle was repeated 
3  –  4 times. Following the last cycle, cells were cul-
tured for 3  –  4 days in maintenance medium. Then 
the cells were stained with Oil Red O. 
  For the chondrogenic differentiation assay, 1.5 mL 
NH ChondroDiff medium (130-091-679; Milentyi 
Biotec, Bergisch Gladbach, Germany) supplemented 
with 100 U penicillin and 100   μ  g streptomycin/mL 
medium was used. The differentiation medium was 
changed after 3 or 4 days. After 24 days, staining 
with methylene blue according to L  ö  fﬂ  er was done. 
MSC were washed with PBS, then methylene blue 
was added for 90 min. Staining solution was removed 
and acetous distilled water (six drops of acetatic acid 
in 100 mL distilled water) added for a few seconds. 
Then     4  °  C distilled water was added and slides were 
washed twice with distilled water. 
  For the osteogenic differentiation, 1.5 mL NH 
OsteoDiff medium (130-091-678; Miltenyi Biotec) 
supplemented with 100 U penicillin and 100   μ  g/mL 
medium streptomycin was used. The differentiation 
medium was changed every 3 or 4 days. At day 10, 
cells were Fast Blue  ®   stained. For each differen-
tiation assay, non-induced MSC were cultured as 
negative controls.     
  Confocal laser scanning microscopy 
  Images were taken with Fluoview software on a Flu-
oview 300 (Olympus, Hamburg, Germany) equipped 
with an IX71 with two lasers, 488 and 543 nm, 
and a 60      oil lens. PMI was excited by 488 nm 
laser light. For imaging of the cell membrane, 1   μ  L 
CellMask  ™  Orange (Invitrogen, Grand Island, NY, 966  G. Schmidtke-Schrezenmeier et al. 
of 100   μ  g/mL for 24 h and stimulated or not by 
10 ng/mL interferon (IFN)-  γ   and 15 ng/mL TNF-  α   
(R&D Systems) for 48 h. Supernatants were then har-
vested to assess indoleamine-2,3 dioxygenase (IDO) 
activity by measuring kynurenin concentration using 
high-performance liquid chromatography (HPLC) 
as described previously (42). CFSE-labeled T and 
NK cells were activated with 0.5   μ  g/mL anti-CD3 
and anti-CD28 antibodies (Sanquin, Amsterdam, 
The Netherlands) or 100 IU/mL recombinant inter-
leukin (IL)-2 (Novartis, East Hanover, NJ, USA), 
respectively. Labeled or unlabeled MSC were added 
at a 1:10 MSC:T and 1:1 MSC:NK ratios. Prolif-
eration of CFSE        Topro-3    –     viable T and NK cells 
was assessed on day 5 of co-culture. The percent-
age of cells in each individual peak corresponding to 
cell generation was quantiﬁ  ed using ModFit LT 3.0 
software (Verity Software, Topsham, ME, USA).     
  MRI 
  For phantom test samples, freshly prepared, cleared, 
liquid agarose 2% in PBS was placed in an agarose 
mold prepared 24 h before. Deﬁ  ned cell numbers 
diluted in 0.5 mL PBS were mixed thoroughly in 
liquid agarose specimens. For   in vivo   imaging, White 
Wistar rats with a weight of about 550  –  610 g were 
used, after obtaining regulatory approval according to 
the German animal protection act. Particle-labeled 
and unlabeled (negative control) MSC were surgi-
cally implanted subcutaneously, mixed in a collagen 
scaffold (Amedrix, Esslingen, Germany). A 3-Tesla 
clinical-grade MRI scanner with a sense ﬂ  ex coil 
(Achieva; Philips, Einhoven, The Netherlands) was 
used for imaging. T1 relaxation time (also called spin-
lattice or longitudinal relaxation time), T2 relaxation 
time (also called spin – spin relaxation time or trans-
verse relaxation time) and the time constant for the 
observed decay of the free induction decay, i.e. the 
T2∗ relaxation time was measured.     
  Statistics 
  Each test was repeated at least twice and three inde-
pendent samples were measured for each data point 
and evaluated by descriptive statistics, unless indicated 
otherwise. Data points represent the mean      stan-
dard deviation unless indicated otherwise.       
  Results 
  For the experiments, different particle batches were 
used (MU-Wuest 1  –  4, with a particle diameter 
between 113 and 124 nm, a surface charge between 
  –  28 and   –  44 mV and an iron content ranging from 
2.32 to 2.72 mg/ mL). A transmission electron 
human tumor necrosis factor (TNF)-  α   (R&D Systems, 
Wiesbaden, Germany), which is known to induce 
expression of adhesion molecules on HUVEC and 
increase the number of adhered cells (41). MSC 
were trypsinized, dispersed in 37  °  C pre-warmed 
  N    2  -hydroxyethylpiper-azine-   N    2  -ethanesulfonic acid 
(HEPES)-buffered salt solution (HBSS) substituted 
with 1% human plasma, and kept at 37  °  C before 
use as a single-cell suspension. Within 60 min, 10  6   
MSC were ﬂ  ushed over the HUVEC at a calculated 
wall shear stress of 0.1 dynes/cm  2  , as described previ-
ously (41). After 5 min, when all MSC had passed 
the endothelial layer, numbers of adhered MSC were 
documented in representative ﬁ  elds using a charge-
coupled device (CCD) camera; then the medium 
ﬂ  ow rate was increased to 2 dynes/cm  2   for 5 min. 
After this, adherent cell numbers were determined 
again (41).     
  CFU-F 
  To test clonogeneity, labeled and unlabeled MSC 
were seeded at different concentrations (3, 9, 18 or 
54 cells/cm  2  ) in standard alpha-MEM in six-well 
plates. After 14 days Giemsa staining was per-
formed and the colonies were macroscopically and 
microscopically evaluated. A colony was deﬁ  ned as a 
concentric cell assembly      50 cells.     
  Proliferation test 
  A CyQuant  ®  Cell proliferation assay (C7026; Invit-
rogen, Paisley, UK) was performed. Cells were tryp-
sinated and 200 cells/well were seeded per 24-well 
plate in 0.5 mL standard medium/well. In parallel, 
triple negative controls with 200 cells and 2000 cells 
were frozen at   –  80  °  C and stained and measured 
together with the cultivated cells. At day 7 optical 
microscopic judgments were made; samples were 
frozen at   –  80  °  C for at least 1 h. For staining and 
lysis, 19 mL distilled water were mixed with 1 mL 
of the kit buffer and 50   μ  L of the dye. Optical mea-
surement was done via a multidetection microplate 
reader, Polarstar Omega (BMG Lab Tec, Offenburg, 
Germany).     
  Assessment of immunosuppressive properties 
  Peripheral blood samples from healthy volunteers 
were provided by the French Blood Bank (EFS, 
Rennes, France). T and NK cells were puriﬁ  ed using 
magnetic-negative cell selection kits (purity     97%; 
Miltenyi Biotech) before staining with 0.2   μ    M   car-
boxyﬂ   uorescein succinimidyl ester (CFSE; Inter-
chim, Montlugon, France). MSC were labeled or 
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increasing doses, as shown by FACS measurements 
utilizing the ﬂ  uorescent dye PMI included in the nano-
particles. Cellular uptake occurred rapidly within the 
ﬁ  rst 2 h, reaching a plateau after 18 h (Figure 2a). By 
doubling the incubation concentrations, equal intracel-
lular concentrations could be achieved after 2 h com-
pared with half of the incubation concentration after 
24 h incubation (Figure 2b). 
  Intracellular nanoparticle persistence was demon-
strated for up to at least 14 days after iron oxide  –  PLLA 
particle removal with Prussian blue staining (Supple-
mentary Figure 2 to be found online at: http://www.
informahealthcare.com/cyt/10.3109/14653249.2011.
571246), up to at least 8 days with TEM imaging 
and up to at least 6 days with FACS measurements. 
This did not preclude the particles persisting in the 
cells even longer. Directly after incubation, high intra-
cellular nanoparticles levels were reached. Within 
24 h of particle removal, intracellular nanopar-
ticle levels dropped sharply and thereafter showed 
slowly descending intracellular levels (Figure 3a, b). 
We wondered whether intracellular persistence might 
microscopy (TEM) image of particle MU-Wuest 1 
is shown in Figure 1a. 
  For the intracellular uptake, persistence and tox-
icity measurements, MSC were incubated for 24 h 
with nanoparticles and evaluated by TEM, confo-
cal laser scanning microscopy (CLSM), ﬂ  uorescent-
activated cell sorting (FACS) and Prussian blue 
staining. 
  The nanoparticles showed excellent intracellu-
lar uptake, as demonstrated by TEM (Figure 1b), 
CLSM and FACS (Supplementary Figure 1a, b to 
be found online at: http://www.informahealthcare.
com/cyt/10.3109/14653249.2011.571246). All MSC 
were labeled after incubation with the nanoparticles. 
Only minor nanoparticle attachments could be identi-
ﬁ  ed on the cell surface. Iron oxide  –  PLLA nanoparti-
cles were taken up with a linear uptake increase with 
        Figure 1.        (a) TEM image of particle MU-Wuest 1 (the bar represents 
100 nm); (b) representative example of a TEM image of MSC 
(passage 11) after 24 h incubation with MU-Wuest 1, showing 
endosomal particle agglomerates. The bar represents 300 nm.   
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        Figure 2.         (a) FACS measurements showing the normalized relative 
ﬂ  uorescence intensity (nFL1) of MSC (passage 5) incubated for 
2, 4, 6, 18 and 24 h, respectively, with MU-Wuest 3 at a dose of 
100   μ  g Fe/mL incubation medium. Results represent median      
standard deviation of triplicates. (b) FACS measurements showing 
the nFL1 intensity of MSC (passage 6) incubated for 24 h with 
MU-Wuest 3 100   μ  g Fe/mL or incubated for 2 h with 150   μ  g and 
200   μ  g MU-Wuest 3, respectively. Results represent mean      
standard deviation of triplicates.   968  G. Schmidtke-Schrezenmeier et al. 
Figure 3 to be found online at: http://www.infor-
mahealthcare.com/cyt/10.3109/14653249.2011.
571246). No inﬂ  uence of iron oxide  –  PLLA particle 
labeling on the typical surface antigen pattern, as 
deﬁ  ned by ISCT, could be found (Figure 5). Differ-
ences between labeled and unlabeled cells could be 
identiﬁ  ed with regard to CD71 (transferrin receptor). 
Whereas with the unlabeled MSC, CD71 expression 
increased after reseeding, in the iron oxide  –  PLLA 
particle-labeled MSC, CD71 expression decreased 
following reseeding after labeling and then returned 
to the basic value at day 14 (Supplementary Figure 4 
to be found online at: http://www.informahealthcare.
com/cyt/10.3109/14653249.2011.571246). 
differ between labeling protocols with a short incuba-
tion of high concentrations and vice versa. We found 
that there was no difference in intracellular persis-
tence between the 2 h/200   μ  g Fe and 24 h/100   μ  g 
Fe labeling protocols (Figure 3a,b). Reseeding of the 
labeled cells at a low density (5     10  3   cells/cm  2  ) resulted in 
lower intracellular particle persistence in compa  ri  son 
with high-density seeded (2      10  4   cells/cm  2  ) labeled 
MSC. As there was less contact inhibition and 
more proliferation under the conditions of 5      10  ³   
cells/cm  ²  , this could indicate a distribution of the par-
ticles to daughter cells during cell division (Figure 3). 
No short- or long-term impact of iron oxide  –  PLLA 
nanoparticle labeling on MSC viability, as determined 
by FACS measurements and 7-AAD staining, could 
be identiﬁ   ed (Figure 4). No inﬂ   uence of the iron 
oxide  –  PLLA nanoparticle labeling on the MSC adi-
pogenic, chondrogenic and osteogenic MSC differ-
entiation potential could be detected (Supplementary 
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        Figure 3.         FACS measurements showing the nFL1 intensity of 
MSC (passage 5) incubated for 24 h with 100   μ  g Fe/mL (a) or 
incubated for 2 h with 200   μ  g Fe/mL MU-Wuest 3 (b) and then 
trypsinated and reseeded at high (20 000 cells/cm  2  ) and low (5000 
cells/cm  2  ) densities. FACS measurements were done directly after 
incubation (0 h) and 24, 48, 96 and 144 h after particle removal 
and reseeding. Results represent mean      standard deviation of 
triplicates. Most of the standard deviations are too small to be 
seen in this graph.   
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        Figure 4.         Relative proportion of living, apoptotic and dead cells 
as assessed by FACS measurements of 7-AAD-stained (a) MSC 
(passage 8), which were incubated for 24 h with MU-Wuest 3 in 
doses from 25   μ  g Fe/mL up to 250   μ  g Fe/mL, and (b) MSC 
incubated for 24 h with MU-Wuest 3 (100   μ  g Fe/mL) and then 
reseeded (5      10  3   and 2      10  4   cells/cm  2  ) and followed-up 144 h 
after reseeding. Results represent mean      standard deviation of 
triplicates. Dotted lines represent unlabeled control cells.      Nanoparticle labeling of MSC for MRI     969
accumulation and the resistance to increased shear 
stress (Figure 6). 
  The role of MSC as modulators of immune 
responses is crucial for their clinical potential, making 
it mandatory to check that this immunosuppressive 
function is preserved after iron-labeling. Importantly, 
the capacity of MSC to inhibit both T and NK cell 
proliferation was not altered by nanoparticle labeling 
(Figure 7a). In addition, we conﬁ  rmed that condi-
tioning of MSC by a combination of IFN-  γ  /TNF-  α   
reinforced their immunosuppressive properties and 
demonstrated that the capacity of MSC to respond 
to these inﬂ  ammatory stimuli was not modiﬁ  ed after 
nanoparticle labeling, as revealed by their increased 
capacity to inhibit both T and NK cell proliferation 
(Supplementary Figure 7 to be found online at: http://
www.informahealthcare.com/cyt/10.3109/14653249.
2011.571246). In agreement, whereas iron-labeling 
  No inﬂ  uence of labeling on the clonogenicity as 
evaluated by CFU-F assay could be observed (Sup-
plementary Figure 5 to be found online at: http://
www.informahealthcare.com/cyt/10.3109/14653
249.2011.571246). The inﬂ   uence of iron oxide  –
  PLLA nanoparticle labeling on MSC proliferation 
was tested using a CyQuant  ®   assay. No inﬂ  uence of 
particle labeling on the proliferation behavior of the 
MSC could be discovered (Supplementary Figure 6 
to be found online at: http://www.informahealthcare.
com/cyt/10.3109/14653249.2011.571246). 
  The inﬂ  uence of iron oxide  –  PLLA nanoparticle 
labeling on adhesion of MSC was studied in a test 
model where the adhesion capability of MSC to a 
HUVEC cell layer, which had been pre-stimulated 
by TNF-  α  , was determined under shear stress. 
Once again, no difference between labeled and unla-
beled cells could be found, both in the rate of initial 
        Figure 5.         Expression of CD45, CD3, CD19, CD14, CD16, CD19, CD11b, CD9, CD13, CD73, CD90, CD105, CD166, HLA-A, -B, 
-C and HLA-DR on unlabeled control MSC and MSC 48 h after labeling with MU-Wuest 3 (passage 4 MSC). Thin lines show isotype 
controls and bold lines the expression of the respective surface antigen.   970  G. Schmidtke-Schrezenmeier et al. 
for the 5      10  4   cells/mL sample. A signal difference 
could also be seen between the high and low density-
seeded cell samples, with the low density showing 
a weaker signal than the high density-seeded cells 
(Supplementary Figure 8 to be found online at: http://
www.informahealthcare.com/cyt/10.3109/14653249.
2011.571246). Signal quantiﬁ   cation matched the 
optical ﬁ  ndings and thus again showed consistency 
with the FACS data.   In vivo   imaging properties were 
tested by implanting 1      10  6   PLLA particle-labeled 
human MSC, mixed in a 1-mL collagen scaffold in 
3      2      3-mm pieces, subcutaneously in a rat. The 
implant was followed-up with multiple MRI ses-
sions up to 25 days after implantation. The implant 
showed an excellent signal with no deterioration over 
time, indicating that the cells did not migrate out of 
the scaffold (Figure 8). Histologic evaluation of the 
implanted scaffolds stained with HE and Prussian blue 
showed spindle-shaped cells with cytoplasmatic iron, 
located exclusively in the collagen scaffold. This ﬁ  nd-
ing was consistent with the MRI observation. In 
another rat it could be shown that 0.8      10  6   MSC/mL 
collagen gel implanted 24 h after particle removal 
(i.e. having a much lower particle load according 
to the kinetic experiments) still showed good vis-
ibility after implantation, with a decreasing and ﬁ  nally 
vanis  hing signal at 35 days after implantation.     
  Discussion 
  Iron labeling of MSC for MRI is a frequently pub-
lished procedure, however most publications focus on 
short-term uptake and follow-up   in vivo   and on the 
basic assessment of differentiation capability. To exploit 
the promise and potential of this method fully, for reg-
ulatory purposes on somatic cell therapeutics and for 
correct interpretation of   in vivo   imaging data, more 
knowledge on the subcellular distribution, retention 
of particles in cycling and quiescent cells and particle 
inﬂ  uence on the MSC phenotype and functionality, 
is necessary. In the past the focus has been on super-
paramagnetic iron oxides (SPIO) already approved 
for use in humans. However, in most MSC-labeling 
regimens SPIO are to be used together with transfec-
tion agents for efﬁ  cient intracellular labeling and, if 
used without, relevant amounts of the SPIO stick on 
the surface of the cells (19  –  21,26,44). One of the most 
suitable ones, Resovist  ®  , was recently removed from 
the market, thus stressing a demand for an innovative, 
non-interfering MRI contrast agent for cell labeling. 
  Uptake kinetics of nanoparticles depends on the 
polymer, surface charge, surface functionalization 
and size of the particle. Whereas some particles are 
taken up slowly and reach their maximum uptake 
only after 24 h or even later, for example polysty-
rene-based particles (24), others are taken up very 
of MSC did not promote IDO activity by itself, 
labeled and unlabeled MSC displayed a similarly 
high IDO activity in the presence of IFN-  γ   and 
TNF-  α   (Figure 7b). 
  It has been reported that intracellular iron oxide 
shows a pronounced   T    2  *     effect (22) and that the 
difference of   T    2  /  T    2  *     may even help to discriminate 
extracellular from intracellular iron oxide (43). 
Agarose phantoms prepared with different particle 
concentrations showed that the native iron oxide  –
  PLLA particles already exerted a pronounced   T    2  *    
effect and only a weak   T    2   effect in contrast to an 
equal   T    2  /  T    2  *     effect of a carboxydextran-coated, for-
merly commercially available, iron oxide contrast 
agent (Resovist  ®  ; Bayer-Schering-Pharma), indi-
cating that the steric arran  gement of the iron oxide 
maybe the main con  tri  butor to this effect. This 
was also reﬂ  ected in the relaxi  vity values   r    2   and   r    2  *    
(1/  T    2  , 1/  T    2  *    , respectively; Supplementary Table I to 
be found online at: http://www.informahealthcare.
com/cyt/10.3109/14653249.2011.571246). Also 
in the agarose phantoms with iron oxide  –  PLLA 
nanoparticle-labeled MSC,   T    2  *     showed the most 
pronounced effect. 
  To investigate whether MRI data matched the 
FACS data with regard to cellular particle reten-
tion, an agarose phantom was prepared loaded with 
samples of 2      10  5   or 5      10  4   MU-Wuest 3-labeled 
cells/mL agarose, directly after labeling and 24 and 
96 h after reseeding with labeling at high (2      10  4   
cells/cm  2  ) or low (5      10  3   cells/cm  2  ) densities, 
respectively. Images matched the FACS data, show-
ing the strongest   T    2  *    signal directly after labeling in 
the 2      10  5   cell/mL sample, with decreasing signal 
strength at 24 and 96 h. An identical ﬁ  nding applied 






































        Figure 6.         MSC adhesion under shear stress showing the number 
of adherent cells on a HUVEC cell layer pre-stimulated with TNF-
  α  . MSC were labeled with MU-Wuest 3 at 100   μ  g Fe/mL for 24 
h and thereafter tested. MSC were adhered to HUVEC under ﬂ  ow 
at 0.1 dynes/cm  2  . The resistance of the adhered cells to increased 
shear stress was determined after raising the shear stress to 2.0 
dynes/cm  2  . Results indicate mean      standard deviation of a total 
of six experiments using three different MSC lines (passages 4, 6 
and 10).      Nanoparticle labeling of MSC for MRI     971
The uptake kinetics of the PLLA particles studied in 
our studies is very similar to the uptake pattern of 
PLLA or poly(ε    -caprolactone) particles into HeLa 
cells (45). It is notable that the dose  –  uptake correla-
tion did not show saturation up to the highest con-
centration tested. This is in agreement with saturation 
rapidly, for example polyisoprene particles, which 
reach a plateau after approximately 4 h of incubation 
(25). Compared with this, the PLLA particles stud-
ied here show a rather fast uptake, with about a 70% 
uptake reached after 2 h and a slow increase of label 
intensity up to 24 h (the last time-point measured). 
        Figure 7.         (a) Proliferation of puriﬁ  ed T and NK cells in response to CD3/CD28 cross-linking or IL-2, respectively. CFSE dilution was 
evaluated on day 5 of culture without MSC (upper panels) or in the presence of unlabeled (middle panels) or labeled (lower panels) MSC. 
MSC (passage 1) were labeled with MU-Wuest 4 100   μ  g Fe/mL for 24 h. Results are expressed as the percentage of T or NK cells that 
had undergone more than one cell division; one representative experiment of two. (b) MSC previously labeled or not with nanoparticles 
were treated with IFN-  γ  /TNF-  α   for 2 days and IDO activity was assessed by quantiﬁ  cation of kynurenin in cell supernatants; one 
representative experiment of two.   972  G. Schmidtke-Schrezenmeier et al. 
MRI detection over a prolonged period. We could 
demonstrate that trifunctional differentiation is not 
inﬂ  uenced by labeling the MSC with iron oxide  –
  PLLA particles. As MSC adhesion is very relevant 
for MSC homing (41), we compared the adhesion 
capability between labeled and unlabeled cells under 
shear stress and could not detect any differences. The 
lack of inﬂ  uence on the clonogenicity of the MSC 
was veriﬁ   ed via CFU-F assays, and an inﬂ  uence 
on the proliferative capabilities of MSC could not 
be demonstrated by proliferation assays. The MSC 
phenotype remained unchanged with regard to the 
basic criteria as deﬁ  ned by the ISCT (9). A differ-
ence between labeled and unlabeled cells was only 
observed for the expression of CD71, the transfer-
rin receptor. CD71 showed a transient difference 
between labeled and unlabeled cells. In accordance 
with our results, others have shown that ferumoxides 
protamine sulfate complexes also result in a transient 
decrease of transferrin receptor mRNA and protein 
(34). In contrast, others have reported that Resovist ®   
without a transfection reagent causes an enhanced 
expression of CD71 (53). Whether our ﬁ  nding is of 
any relevance remains to be elucidated. CD71 plays 
a role in transferrin-bound iron uptake (54). It is 
over-expressed in highly proliferating tissues (55,56) 
and is not expressed in immature progenitor cells 
(56  –  58). CD71 is an endosomal-associated protein 
that is recycled to the plasma membrane after release 
of iron (59,60). The reason for the lack of up-reg-
ulation could be assumed to be the iron loading of 
the cell or the interference of the particle with the 
endosomal receptor recycling pathway. As different 
iron oxide-containing preparations (e.g. Resovist  ®  , 
PLLA nanoparticles and ferumoxides protamine 
sulfate) might differ in intracellular trafﬁ  cking and 
metabolism, the release of iron and the inﬂ  uence on 
iron metabolism might also differ. 
  The immunomodulatory potential of MSC was 
assessed by inhibition of  T and NK cell proliferation 
and by production of functional IDO, an immunosup-
pressive mechanism consistently reported for human 
MSC. No difference could be observed between 
labeled and unlabeled MSC for these parameters, 
indicating that the MSC behavior towards immune 
cells and response to inﬂ   ammatory cytokines was 
unaffected by nanoparticle labeling. This is of par-
ticular interest as the immunosuppressive properties 
of MSC are usually triggered by inﬂ  ammatory signals 
and are crucial for their   in vivo   efﬁ  cacy. 
  The suitability of the particles for   in vivo   imag-
ing has also been demonstrated by the ﬁ  rst   in vivo   
studies in rats.   T    2  *     qualiﬁ  ed as lead parameter in 
the MRI quantiﬁ  cation, with clear dose- and time-
dependency and clear differences between labeled and 
kinetics of other nanoparticles synthesized by the 
mini-emulsion process, such as PBCA particles (46) 
and polyisoprene particles (25). 
  The uptake of nanoparticles can happen via vari-
ous endocytotic mechanisms (47). Like many other 
particles, the iron oxide  –  PLLA particles end up in 
endosomes (21,47,48). The results on intracellular 
particle persistence are consistent with published lit-
erature, where different iron-labeling regimens have 
been used (22,23,49  –  52). 
  There are publications reporting an inﬂ  uence of 
iron labeling on MSC biology. For iron labelling 
additional transfection agents are frequently nec-
essary. These transfection agents might inﬂ  uence 
MSC biology (31,33). The goal of iron labeling 
MSC is to gain more insight into the   in vivo   behav-
ior of MSC. Iron oxide  –  PLLA particles have been 
developed recently (36). They have the advantage 
of full biodegradability of the polymer (38). Our 
investigation demonstrated undisturbed cell viability, 
even with high particle concentrations, and a long-
lasting intracellular retention that is sufﬁ  cient  for 
        Figure 8.         1      10  6   MSC (passage 4) labeled with MU-Wuest 4 
100   μ  g Fe/mL in 1 mL of a collagen scaffold 2      3      2-mm 
subcutaneous implant. (a) MRI taken 2 days after implantation; 
(b) MRI 25 days after implantation. As a control, the same number 
of unlabeled MSC in a scaffold was implanted on the contralateral 
side. No   T    2  /  T    2  *    signal could be detected at the implantation site 
of the control.      Nanoparticle labeling of MSC for MRI     973
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We showed that the iron oxide  –  PLLA-labeled MSC 
are easily detectable in MRI   in vitro   and   in vivo   and 
thus present a promising tool for elucidating the func-
tion of MSC and optimization of an application mode 
in addition to homing and trafﬁ  cking   in vivo   by 
non-invasive MRI, thus also fulﬁ  lling the regulatory 
requirements for data on biodistribution of MSC. 
  In conclusion, it was demonstrated that iron 
oxide  –  PLLA particles are promising candidates for 
MSC labeling for MRI because they did not change 
the MSC biology in the comprehensive   in vitro   test 
settings applied, and showed excellent MRI prop-
erties over several weeks, as demonstrated in rats. 
This method could also help us gain more insight 
not only regarding the homing and trafficking of 
MSC but also in their mode of action in differ-
ent indications, and provide relevant guidance for 
the optimal application mode of MSC in different 
indications.     
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